NO324659B1 - Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. - Google Patents
Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. Download PDFInfo
- Publication number
- NO324659B1 NO324659B1 NO19994138A NO994138A NO324659B1 NO 324659 B1 NO324659 B1 NO 324659B1 NO 19994138 A NO19994138 A NO 19994138A NO 994138 A NO994138 A NO 994138A NO 324659 B1 NO324659 B1 NO 324659B1
- Authority
- NO
- Norway
- Prior art keywords
- vwf
- activity
- factor
- fraction
- multimers
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 108010047303 von Willebrand Factor Proteins 0.000 title claims description 246
- 102100036537 von Willebrand factor Human genes 0.000 title claims description 232
- 238000005277 cation exchange chromatography Methods 0.000 title claims description 31
- 229960001134 von willebrand factor Drugs 0.000 title description 206
- 238000011084 recovery Methods 0.000 title description 7
- 230000000694 effects Effects 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 150000001768 cations Chemical group 0.000 claims abstract description 25
- 238000010828 elution Methods 0.000 claims abstract description 20
- 239000000872 buffer Substances 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 238000000746 purification Methods 0.000 claims description 30
- 238000005571 anion exchange chromatography Methods 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 238000001042 affinity chromatography Methods 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 208000009292 Hemophilia A Diseases 0.000 claims description 5
- 230000004520 agglutination Effects 0.000 claims description 5
- 239000012460 protein solution Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000031220 Hemophilia Diseases 0.000 claims description 3
- -1 sulfopropyl Chemical group 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 113
- 239000011780 sodium chloride Substances 0.000 description 58
- 150000001450 anions Chemical class 0.000 description 29
- 239000000243 solution Substances 0.000 description 19
- 108010054218 Factor VIII Proteins 0.000 description 10
- 102000001690 Factor VIII Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229960000301 factor viii Drugs 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 238000005341 cation exchange Methods 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 239000007858 starting material Substances 0.000 description 7
- 102100026735 Coagulation factor VIII Human genes 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 238000005349 anion exchange Methods 0.000 description 6
- 238000011210 chromatographic step Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229910001679 gibbsite Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Detergent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Water By Ion Exchange (AREA)
- Confectionery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0033797A AT405403B (de) | 1997-02-27 | 1997-02-27 | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| PCT/AT1998/000034 WO1998038219A1 (fr) | 1997-02-27 | 1998-02-18 | Purification du facteur de von willebrand par chromatographie sur echangeur de cations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO994138D0 NO994138D0 (no) | 1999-08-26 |
| NO994138L NO994138L (no) | 1999-08-26 |
| NO324659B1 true NO324659B1 (no) | 2007-11-26 |
Family
ID=3487918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19994138A NO324659B1 (no) | 1997-02-27 | 1999-08-26 | Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6465624B1 (fr) |
| EP (1) | EP1005492B1 (fr) |
| JP (1) | JP4250770B2 (fr) |
| AT (2) | AT405403B (fr) |
| AU (1) | AU737986B2 (fr) |
| CA (1) | CA2282843C (fr) |
| DE (1) | DE59813967D1 (fr) |
| DK (1) | DK1005492T3 (fr) |
| ES (1) | ES2285754T3 (fr) |
| NO (1) | NO324659B1 (fr) |
| WO (1) | WO1998038219A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| US6531577B1 (en) * | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| AT408443B (de) * | 1998-02-27 | 2001-11-26 | Immuno Ag | Verfahren zur gewinnung von gereinigtem faktor viii:c/vwf-komplex |
| US6605222B1 (en) * | 1998-05-20 | 2003-08-12 | Baxter Aktiengesellschaft | Method for producing a factor VIII/von Willebrand factor complex |
| FR2874216B1 (fr) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
| BRPI0514984A (pt) | 2004-09-07 | 2008-07-01 | Archemix Corp | aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica |
| US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| JP2008512097A (ja) * | 2004-09-07 | 2008-04-24 | アーケミックス コーポレイション | アプタマー医薬品化学 |
| DE102004044419B4 (de) | 2004-09-14 | 2010-04-15 | Biotest Ag | Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie |
| DE102004044429B4 (de) | 2004-09-14 | 2009-04-30 | Biotest Ag | Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor |
| EP1835938B1 (fr) | 2004-12-27 | 2013-08-07 | Baxter International Inc. | Conjugues entre polymeres et facteurs von willebrand |
| US7683158B2 (en) | 2006-03-31 | 2010-03-23 | Baxter International Inc. | Pegylated factor VIII |
| WO2008150495A2 (fr) * | 2007-06-01 | 2008-12-11 | Archemix Corp. | Formulations d'aptamère vwf et procédés d'utilisation |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| EP3936116A1 (fr) * | 2007-12-28 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Formulations comprenant de vwf recombinant |
| PT2349314E (pt) * | 2008-10-21 | 2013-05-28 | Baxter Int | Formulações de vwf recombinante liofilizado |
| AU2010284116B9 (en) * | 2009-08-20 | 2015-03-26 | Takeda Pharmaceutical Company Limited | Purification of VWF for increased removal of non-lipid enveloped viruses |
| CA2821711C (fr) | 2010-12-15 | 2017-10-10 | Baxter International Inc. | Recuperation d'eluat par utilisation d'un gradient de conductivite |
| EP3858375B1 (fr) * | 2011-06-10 | 2024-03-20 | Takeda Pharmaceutical Company Limited | Traitement d'une maladie de la coagulation par l'administration du fvw recombinant |
| WO2015188224A1 (fr) | 2014-06-13 | 2015-12-17 | Csl Limited | Production améliorée du facteur de von willebrand recombinant dans un bioréacteur |
| PT3648788T (pt) | 2017-07-07 | 2024-08-23 | Takeda Pharmaceuticals Co | Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante |
| AU2019240135B2 (en) | 2018-03-21 | 2024-10-03 | Takeda Pharmaceutical Company Limited | Separation of VWF and VWF propeptide by chromatographic methods |
| CA3161383A1 (fr) | 2019-12-10 | 2021-06-17 | Vera OTT | Procede de fabrication d'une preparation de fibrinogene |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361509A (en) | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US5006642A (en) | 1987-06-29 | 1991-04-09 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Purification of von Willebrand Factor by affinity chromatography |
| FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| DE3904354A1 (de) | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
| FR2665449B1 (fr) * | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. |
| NZ237244A (en) * | 1990-03-02 | 1992-10-28 | Bio Technology General Corp | Cloning and production of human von willebrand factor analogues and compositions thereof |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| IT1256622B (it) * | 1992-12-04 | 1995-12-12 | Sclavo Spa | Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale. |
| CA2159044A1 (fr) | 1994-09-26 | 1996-03-27 | Falko-Guenter Falkner | Methode de dosage des acides nucleiques |
| AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| DE4435392B4 (de) | 1994-10-04 | 2008-02-07 | Immuno Ag | Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF |
| US5887152A (en) | 1995-04-12 | 1999-03-23 | Advanced Micro Devices, Inc. | Load/store unit with multiple oldest outstanding instruction pointers for completing store and load/store miss instructions |
-
1997
- 1997-02-27 AT AT0033797A patent/AT405403B/de not_active IP Right Cessation
-
1998
- 1998-02-18 WO PCT/AT1998/000034 patent/WO1998038219A1/fr active IP Right Grant
- 1998-02-18 AU AU58470/98A patent/AU737986B2/en not_active Expired
- 1998-02-18 JP JP53705698A patent/JP4250770B2/ja not_active Expired - Lifetime
- 1998-02-18 AT AT98901870T patent/ATE359301T1/de active
- 1998-02-18 DE DE59813967T patent/DE59813967D1/de not_active Expired - Lifetime
- 1998-02-18 EP EP98901870A patent/EP1005492B1/fr not_active Expired - Lifetime
- 1998-02-18 DK DK98901870T patent/DK1005492T3/da active
- 1998-02-18 CA CA002282843A patent/CA2282843C/fr not_active Expired - Lifetime
- 1998-02-18 ES ES98901870T patent/ES2285754T3/es not_active Expired - Lifetime
- 1998-02-18 US US09/367,460 patent/US6465624B1/en not_active Expired - Lifetime
-
1999
- 1999-08-26 NO NO19994138A patent/NO324659B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001513088A (ja) | 2001-08-28 |
| EP1005492B1 (fr) | 2007-04-11 |
| JP4250770B2 (ja) | 2009-04-08 |
| NO994138D0 (no) | 1999-08-26 |
| WO1998038219A1 (fr) | 1998-09-03 |
| NO994138L (no) | 1999-08-26 |
| EP1005492A1 (fr) | 2000-06-07 |
| AU737986B2 (en) | 2001-09-06 |
| CA2282843C (fr) | 2008-12-02 |
| ES2285754T3 (es) | 2007-11-16 |
| DK1005492T3 (da) | 2007-08-13 |
| AT405403B (de) | 1999-08-25 |
| CA2282843A1 (fr) | 1998-09-03 |
| ATE359301T1 (de) | 2007-05-15 |
| US6465624B1 (en) | 2002-10-15 |
| ATA33797A (de) | 1998-12-15 |
| AU5847098A (en) | 1998-09-18 |
| DE59813967D1 (de) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324659B1 (no) | Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. | |
| JP3701028B2 (ja) | 高純度フォンビルブラント因子の入手方法 | |
| EP0503991B1 (fr) | Procédé de préparation à l'échelle industrielle d'un concentré de facteur von Willebrand humain standardisé, de très haute pureté, approprié à un usage thérapeutique | |
| CN104981476B (zh) | 一种纯化治疗性蛋白质的方法 | |
| RU2603103C2 (ru) | Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт | |
| EP2078730B9 (fr) | Procédé pour obtenir un concentré de facteur Von Willebrand ou complexe de facteur VIII/facteur Von Willebrand et utilisation associée | |
| FI95654B (fi) | Menetelmä veren hyytymistekijän VIII ja von Willebrand-tekijän kompleksin konsentraatin valmistamiseksi kokoplasmasta | |
| JP4250771B2 (ja) | カチオン交換クロマトグラフィーによる因子ＶＩＩＩ／ｖＷＦ複合体の精製方法 | |
| AU2003244850B2 (en) | Processes for the preparation of fibrinogen | |
| JP2000506869A (ja) | 安定な因子ｖｉｉｉ／▲下ｖ▼ｗｆ複合体 | |
| CA2697404A1 (fr) | Procede de purification du facteur viii et du facteur von willebrand | |
| JP2009161547A (ja) | 高度に精製された第ｖｉｉｉ因子コンプレックス | |
| DK162233B (da) | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii | |
| JPS6160614A (ja) | 第８因子製剤およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAXALTA INCORPORATED, CH |
|
| MK1K | Patent expired |